ArticleFrontiers in immunology2020
Intravital Imaging of Adoptive T-Cell Morphology, Mobility and Trafficking Following Immune Checkpoint Inhibition in a Mouse Melanoma Model.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 43 citations in OpenAlex.
- Review
- GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.Nature cancer · 2026Article
- Organ-Specific Migration License (OSML) theory: a novel paradigm for spatiotemporal regulation and intervention of cross-organ immune cell migration in tumor immune responses.Cell communication and signaling : CCS · 2026Review
- Plying potency assays for immunotherapy of solid tumors.Frontiers in immunology · 2026Review
- Methods to analyze cell migration data: fundamentals and practical guidelines.Nature methods · 2026Review
- Macrophage repolarization by immune checkpoint blockade drives T cell engagement in the tumor microenvironment.iScience · 2025Article
- Deriving the A/B Cells Policy as a Robust Multi-Object Cell Pipeline for Time-Lapse Microscopy.International journal of molecular sciences · 2025Article
- Intravital Imaging of Immune Responses in the Cancer Microenvironment.Cancer medicine · 2025Review
- Emerging insights into intravital imaging, unraveling its role in cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2025Review
- Imaging antigen processing and presentation in cancer.Immunotherapy advances · 2025Review
- Visualizing cellular interactions: intravital imaging in tumor microenvironment.Frontiers in immunology · 2025Review
- Checkpoint inhibition enhances cell contacts between CD4Haematologica · 2024Article
- Applications of Intravital Imaging in Cancer Immunotherapy.Bioengineering (Basel, Switzerland) · 2024Review
- The peritumor microenvironment: physics and immunity.Trends in cancer · 2023Review
- Intravital imaging of the functions of immune cells in the tumor microenvironment during immunotherapy.Frontiers in immunology · 2023Review
- Volume imaging to interrogate cancer cell-tumor microenvironment interactions in space and time.Frontiers in immunology · 2023Review
- MRI techniques for immunotherapy monitoring.Journal for immunotherapy of cancer · 2022Review
- Review
- Cell Trafficking at the Intersection of the Tumor-Immune Compartments.Annual review of biomedical engineering · 2022Review
- Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation.Molecular imaging and biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Efficient T-cell targeting, infiltration and activation within tumors is crucial for successful adoptive T-cell therapy. Intravital microscopy is a powerful tool for the visualization of T-cell behavior within tumors, as well as spatial and temporal heterogeneity in response to immunotherapy. Here we describe an experimental approach for intravital imaging of adoptive T-cell morphology, mobility and trafficking in a skin-flap tumor model, following immune modulation with immune checkpoint inhibitors (ICIs) targeting PD-L1 and CTLA-4. A syngeneic model of ovalbumin and mCherry-expressing amelanotic mouse melanoma was used in conjunction with adoptively transferred OT-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.